Genmab — Juli 2025
-
A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade https://www.nature.com/articles/s41598-025-11990-z
-
this is what it said last august24: Following a strategic evaluation of GEN1053 within the context of
Genmab’s and BioNTech’s portfolios, a decision was made to discontinue the Phase 1/2 clinical trial
(NCT05435339) of GEN1053 in solid tumors. Preclinical activities remain ongoing. -
Godmorgen
-
Genmab Transcript Special Call: Ser Rina-S i markedet i 2027 med peak-salg på 2 mia. USD https://proinvestor.com/investornyt/1343403/genmab-transcript-special-call-ser-rina-s-i-markedet-i-2027-med-peak-salg-pa-2-mia-usd
-
ESMO 2025 Industry Satellite Symposium
Genmab - Advancing Antibody-Drug Conjugates Into the Future of Gynecologic Malignancies https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal/session/calendar?q=genmab
-
Teknisk: Genmab bryder op gennem 200 MA, mere i vente mandag https://proinvestor.com/investornyt/1343407/teknisk-genmab-bryder-op-gennem-200-ma-mere-i-vente-mandag
-
Ugens danske Vindere & Tabere: Endelig en super-uge for dansk life science https://proinvestor.com/investornyt/1343406/ugens-danske-vindere-amp-tabere-endelig-en-super-uge-for-dansk-life-science
-
Spændende og bekræftende læsning. Og så skal man skrive sig bag øret, at de 2 mia $ kun er i onkologi. Som de angiver virker det sandsynligt, at Rina-S også virker i andre solide kræftformer. Altså er de 2 mis måske slet ikke i nærheden af et muligt topsalg.
-
Bikube, det er de samme 2 AE som blev nævnt i post ASCO præsentationen d. 2 juni. Hvor analytikkerne også spurgte ind til det. En pt havde mange comorbidities og døde as septic shock og den andens død blev ikke bedømt at være grundet Rina-S. Se side 12 . https://genmab-2025-post-asco-virtual-rd-update-june25.open-exchange.net/replay
-
Hov det var videon. Her er præsentation. https://ir.genmab.com/static-files/da696dd4-c1be-4903-83b9-99b73bba55c8
) for patients with advanced or recurrent endometrial cancer (a/r EC): Update from dose expansion cohort B2 of RAINFOL
-01
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind